KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD

By sjmartinez • December 25, 2023

Mottl AK, Nicholas SB. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis. 2023 Dec 21:S0272-6386(23)00883-1. doi: 10.1053/j.ajkd.2023.09.003. Epub ahead of print. PMID: 38142396.

Tags: Chronic kidney disease, commentary, diabetes, evidence-based recommendation, GLP-1 RAs, guideline, guideline implementation, Nephrology, nephrology best practices, ns-MRAs, Publications, SGLT2 inhibitors

Inebilizumab Monotherapy in Relapsing IgG4-Related Tubulointerstitial Nephritis

Ebrahimi N, Ha V, Glassock RJ, Rastogi A, Norouzi S. Inebilizumab Monotherapy in Relapsing IgG4-Related Tubulointerstitial Nephritis. Kidney Int Rep. 2026 Aug 24;11(11):107055. doi: 10.1016/j.ekir.2026.107055.[...]

Comparative Renal Effectiveness of GLP-1RA and SGLT2i in US Veterans with Type 2 Diabetes and CKD

Htoo PT, Patorno E, Ortega-Montiel J, Wexler DJ, Orkaby A, Paik JM. Comparative Renal Effectiveness of GLP-1RA and SGLT2i in US Veterans with Type 2[...]

Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient With Metastatic Renal Cell Carcinoma and Limited Renal Reserve: A Diagnostic Challenge

Goshtaseb R, Luu Y, Sarmosyan K, Lopez L, Drakaki A. Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient[...]